|
Post by mnholdem on Sept 5, 2018 14:23:59 GMT -5
I put dibs on the name “Jiffy Pop”. Oh wait, that’s already taken.
|
|
|
Post by mnholdem on Sept 5, 2018 9:41:17 GMT -5
Did you catch Mike’s comment that one application for the single-use Cricket could be erectile dysfunction?
|
|
|
Post by mnholdem on Sept 5, 2018 8:08:34 GMT -5
It's called churn and burn Well I call it that. Has anyone been following my posts that have been right on? BTW, mytakeonit newsletter price has been raised to $50/month. Sorry, but you know that the wine cost has been rising and I do need to go to Vegas soon ... Send monies to mytakeonit.com Exactly! A few hedge fund managers can trade back and forth to each other all day to (try to) control share price and at the EOD own little more than what they started with.
|
|
|
Post by mnholdem on Sept 5, 2018 8:04:01 GMT -5
She has a vision similar to what Al Mann had IMO.
|
|
|
Post by mnholdem on Sept 4, 2018 22:13:44 GMT -5
MNKD Nasdaq real time volume today, 27,772,027 shares. MNKD Nasdaq summary volume today, 50,777,279 shares. www.nasdaq.com/symbol/mnkdwww.nasdaq.com/symbol/mnkd/real-timeMNKD $2.07* +0.97 +88.18% I had typed more, and lost the post. I will type again, the major jist is, from the 11 something Sanofi high (split in there) and the 6.96 high, the downtrend line is $5.30. that is the next MAJOR resistance to hit and break on our way up. Can someone please explain this to me!? I guess I understand that there are circle sales to keep a price down and short potentially distorting the market value, but what do these numbers up there mean..
Is it really the case, that despite some good news for one of the most oversold companies (in relative value) several million shares (a couple of % of the flow) were traded below 2$? And why would all of the sudden the price go up in the after hours at (I guess) rather low volumes?
What is the idea behind this?
- shorts follow business hours!? - there are share owners selling low on good news? - shorts are relentless and think the price should be lower??
An good idea of what happens here would be really appreciated.. is there a similar case in the past with a reasonable explanation?
Dark pools are an ominous-sounding term for private exchanges or forums for trading securities; unlike stock exchanges, dark pools are not accessible by the investing public. Also known as “dark pools of liquidity,” they are so named for their complete lack of transparency. Dark pools came about primarily to facilitate block trading by institutional investors, who did not wish to impact the markets with their large orders and consequently obtain adverse prices for their trades. While dark pools have been cast in a very unfavorable light in Michael Lewis’ bestseller “Flash Boys: A Wall Street Revolt,” the reality is that they do serve a purpose. However, their lack of transparency makes them vulnerable to potential conflicts of interest by their owners and predatory trading practices by some high-frequency traders.
The lack of transparency actually works in the institutional investor’s favor, since it may result in a better-realized price than if the sale was executed on an exchange. Note that as dark pool participants do not disclose their trading intention to the exchange before execution, there is no order book visible to the public. Trade execution details are only released to the consolidated tape after a delay.
Read more: An Introduction to Dark Pools | Investopedia www.investopedia.com/articles/markets/050614/introduction-dark-pools.asp#ixzz5QC4JHnE5 Follow us: Investopedia on Facebook
Source: An Introduction to Dark Pools | Investopedia www.investopedia.com/articles/markets/050614/introduction-dark-pools.asp#ixzz5QC3Ms5k5
|
|
|
Post by mnholdem on Sept 4, 2018 22:08:01 GMT -5
I totally agree with you, peppy, that UTC will be developing a COPD treatment using Technosphere.
|
|
|
Post by mnholdem on Sept 4, 2018 21:59:51 GMT -5
United Therapeutics strikes nine-figure deal to commercialize new form of drug delivery
By Michael Neibauer – Associate Editor, Washington Business Journal Sep 4, 2018, 7:54am EDT
Excerpts:
United Therapeutics (NASDAQ: UTHR) is licensing a dry powder formulation of treprostinil, the active ingredient in Remodulin, in development by MannKind Corp. (NASDAQ: MNKD). The system is currently in the clinical trials stage.
The deal will expand the delivery methods for Remodulin, now available in intravenous, injectable and oral forms. United Therapeutics will be responsible for the global development, regulatory and commercial activities of the drug's new form.
Westlake Village, California-based MannKind will manufacture clinical supplies and initial commercial supplies out of its Danbury, Connecticut, plant, while United Therapeutics will manufacture long-term commercial supplies of the product.
---
United Therapeutics has a long history with treprostinil and MannKind. Exactly 21 years ago, UT CEO Martine Rothblatt said in a statement, the Maryland company combined one of its creations with a parenteral infusion pump called MiniMed 407c, invented by Alfred Mann, to create Remodulin.
Rothblatt said the new inhalation devices will be "revolutionary."
In late July, United Therapeutics received Federal Drug Administration approval for an implantable pump for Remodulin. The drug, perhaps soon-to-be-available as a generic, generated sales of $286.3 million in the first six months of the year for United Therapeutics.
Source: www.bizjournals.com/washington/news/2018/09/04/united-therapeutics-strikes-nine-figure-deal-to.html
|
|
|
Post by mnholdem on Sept 4, 2018 19:15:02 GMT -5
www.latimes.com/business/la-fi-mannkind-hypertension-deal-20180904-storyMannKind strikes deal for inhalable hypertension treatment, sending stock soaringBy JIM PUZZANGH SEP 4, 2018 - Washington Excerpt: Castagna said the stock price has been hurt by the company’s negative cash flow. He said Afrezza sales have improved each quarter since the start of 2017 and the United Therapeutics deal will help MannKind expand TV advertising for the diabetes treatment. “The more we invest in Afrezza, the faster it grows. … Ninety-nine percent of people with diabetes don’t know inhalable is an option for them,” he said.
|
|
|
Post by mnholdem on Sept 4, 2018 18:37:48 GMT -5
Non-addictive pain management. Expensive development with potentially huge returns.
|
|
|
Post by mnholdem on Sept 4, 2018 16:22:51 GMT -5
Mike stated that improved cash situation (indicated more $ in coming months) will enable MannKind to expand it’s pipeline. What I’d really like to hear is the start of the FDA-mandated lung safety study for Afrezza. This will be especially vital to Afrezza winning approval for pediatric use.
|
|
|
Post by mnholdem on Sept 4, 2018 14:29:16 GMT -5
United Therapeutics’ CEO doesn’t seem to be the kind of person who would stab MannKind in the back. As you mentioned, her company has a COPD candidate in clinical testing. It seems that she could take full advantage of “Your Drug. Our Delivery.” - see MannKind Corporate website Partnering page.
|
|
|
Post by mnholdem on Sept 4, 2018 13:04:32 GMT -5
No what would be really great.... If United Therapeutics takes a stake in mnkd. Yes, a 100% stake for $10! I'm a modest dreamer, what can I say? LOL I always thought of you as leaning toward the immodest side, baba.
|
|
|
Post by mnholdem on Sept 4, 2018 13:02:37 GMT -5
Anyone else see this in the release? “United Therapeutics will manufacture the long-term commercial supplies.” Does this mean that the IP for manufacturing TS is going to be shared with UTHR? I hope they button that up to be sure it doesn’t get away from them. Manufacturing will be licensed, not given away.
|
|
|
Post by mnholdem on Sept 4, 2018 12:59:21 GMT -5
I was not referring to you, just shorts in general.
|
|
|
Post by mnholdem on Sept 4, 2018 11:42:28 GMT -5
United Therapeutics is a biotechnology company. It is listed on the NASDAQ [UTHR]. Its headquarters are located in Silver Spring, Maryland, with additional facilities in Research Triangle Park, North Carolina; Magog, Quebec; Melbourne, Florida; and Manchester, New Hampshire.
History
United Therapeutics was founded in 1996 by Martine Rothblatt, an American lawyer, author, and entrepreneur, who previously created Sirius XM. In 1994, Rothblatt's young daughter was diagnosed with a fatal orphan disease, pulmonary arterial hypertension (PAH). Rothblatt sold her telecom stock and started the $3 million PPH Cure Foundation to fund PAH research. By 2002 the FDA had approved United Therapeutics new drug Remodulin an alternative to GlaxoSmithKline's Flolan. In 2002 Remodulin was priced at $90,000 per year and within "a year annual sales were $50 million." By 2010 sales rose to $300 million.
By 2010, "United Therapeutics shares had increased 800% from 1999 when the company went public.
By October 2012, United Therapeutics had a market capitalization of US$3 billion. Rothblatt received a total compensation of $31,581,896 in 2014. According to the "annual collaborative report" from Equilar and The New York Times, Rothblatt ranked 24th in the list of "200 highest-paid CEOs of large publicly traded companies" and fourth in the list of biopharmaceutical executives with the highest total compensation.
On December 31, 2014, United Therapeutics announced a deal with DEKA for the development of a potential technology breakthrough in the subcutaneous delivery of its Remodulin (treprostinil) injection to patients with pulmonary arterial hypertension (PAH) via a pre-filled semi-disposable pump system. According to Martine Rothblatt, “The new DEKA semi-disposable pump system will advance the convenience and delivery of subcutaneous Remodulin”. Rothblatt is a collaborator on inventions with DEKA's founder Dean Kamen.
Medicines
As of 2017, United Therapeutics markets five medicines with over a dozen new medicines in development. The marketed medicines are Remodulin, Tyvaso, Orenitram and Adcirca for pulmonary arterial hypertension, and Unituxin for neuroblastoma. Clinical trials of new medicines related to pulmonary hypertension include INCREASE for interstitial lung disease, SOUTHPAW for heart failure, PERFECT for COPD and SAPPHIRE for gene therapy. Other medicines being developed include dinutuximab for Small Cell Lung Cancer, and meter dose inhaler preparations for pulmonary selective vasodilation.
United Therapeutics generally develops medicines under a pharmacogenomic paradigm that emphasizes association of clinical trial outcomes with genetic polymorphisms identified from whole genome sequencing of patients enrolled in clinical studies. The company has a goal of ultimately providing prescribing information that includes differential expectations based upon bioinformatic knowledge gained from genome sequencing.
United Therapeutics is also developing a unique type of biologic medicinal product known as a manufactured organ. This type of biologic would be transplanted into the patient as a substitute for a failing organ. The company has regenerative medicine products such as these being developed via xenotransplantation, allogenic recellularization and autologous bioprinting technologies.
Source: en.wikipedia.org/wiki/United_Therapeutics
---
This bio might give MNKD shareholders an idea of some additional API they may be looking to develop with MannKind.
|
|